Mantle Cell Lymphoma

FDA Approves KTE-X19 CAR T-Cell Therapy for R/R Mantle Cell Lymphoma

July 24, 2020

The FDA has approved brexucabtagene autoleucel for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

Discussing How to Treat Patients With Mantle Cell Lymphoma

July 23, 2020

Lori A. Leslie, MD, discusses options for patients with relapsed/refractory mantle cell lymphoma.

CAR T-Cell Therapy Offers Potential Solution for Relapse in MCL, But With Toxicity Risk

July 22, 2020

In a presentation during the 2020 Debates and Didactics in Hematology and Oncology conference, Amelia A. Langston, MD, explained the issues with treating patients with relapsed mantle cell lymphoma and how the integration of chimeric antigen receptor T-cell therapy can be a solution to the problem.

Bortezomib Consolidation or Maintenance Extends Survival With R-CHOP in MCL

July 09, 2020

The addition of bortezomib consolidation therapy or bortezomib maintenance to the immunochemotherapy regimen rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone improved progression-free survival in patients with mantle cell lymphoma in the post-transplant setting, according to a comparative analysis, CALGB/Alliance 50403 trial.

CLL and MCL Survival Benefit From Umbralisib Plus Ibrutinib Holds Up in 4-Year Follow-Up

July 08, 2020

In an interview with Targeted Oncology, Matthew Davids, MD, MMSc, discussed the long-term follow-up results of ibrutinib in combination with umbralisib as treatment of patients with chronic lymphocytic leukemia and mantle cell lymphoma.

Novel BTK Inhibitor Appears Promising in Mantle Cell Lymphoma and Other NHLs

July 02, 2020

In an interview with Targeted Oncology, Gaël Roué, PhD, discussed the rationale for evaluating TG-1701 in combination with ublituximab and umbralisib in ibrutinib-resistant MCL.

FDA Grants Orphan Drug Designation to Cirmtuzumab in MCL and CLL

June 30, 2020

"We are excited about cirmtuzumab’s potential for the treatment of patients with ROR1-expressing cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, HER2-negative breast cancer, and other solid tumors, and look forward to further advancing its development to benefit patients with significant unmet medical needs."

TP53, KMT2D Abnormalities Linked With Poor Prognosis in MCL

June 24, 2020

Patients receiving high-dose therapy for mantle cell lymphoma are at a higher risk of treatment failure if they have mutations in the TP53 or KMT2D genes, according to new research.

Preclinical Models Show Benefit for Novel BTK Inhibitor in MCL, NHL

June 23, 2020

"When compared to ibrutinib, TG-1701 used at high doses retained notable antitumor activity in MCL cells with BTK C481S mutation, while it did not show superior activity than the first-in-class BTK [inhibitor] in in vitro and in vivo models of ibrutinib-resistant MCL with constitutive activation of the non-canonical NF-KB pathway.”

ZUMA-2 Trial Demonstrates Similar Outcomes for High- and Low-Risk MCL

June 11, 2020

Michael Wang, MD, discusses the pharmacological profile of KTE-X19 in patients with high- or low-risk relapsed/refractory mantle cell lymphoma in the ZUMA-2 trial.